Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders
|
|
- Austen Powell
- 6 years ago
- Views:
Transcription
1 FERTILITY AND STERILITY VOL. 72, NO. 1, JULY 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders Pedro Acién, M.D.,* Francisco Quereda, M.D.,* Pilar Matallín, M.D., Encarnación Villarroya, M.D.,* Jose A. López-Fernández, M.D., Maribel Acién, M.D., Monserrat Mauri, M.D., and Rocío Alfayate, M.D. Department of Obstetrics and Gynecology, School of Medicine, Miguel Hernández University, Campus de San Juan, Alicante, Spain Received June 24, 1998; revised and accepted February 17, Reprint requests: Pedro Acién, M.D., Departamento de Ginecologia, Facultad de Medicina, Campus de San Juan, Apartado de Correos 18, San Juan, Alicante, Spain (FAX: ; acien@umh.es). * Service of Obstetrics and Gynecology, San Juan University Hospital. Service of Obstetrics and Gynecology, Alicante University General Hospital. Institute of Gynecology P.A.A. Hormone Laboratory, Alicante University General Hospital /99/$20.00 PII S (99) Objective: To analyze the correlations among insulin, androgens, body mass index (BMI), and other related metabolic anomalies in women with and without polycystic ovary syndrome (PCOS). Design: Retrospective study of normal and obese women with and without PCOS. Setting: Gynecologic endocrinology units of Elche, San Juan, and Alicante Hospitals and Hormone Laboratory at Alicante University Hospital ( Miguel Hernández University). Patient(s): A total of 212 women were studied: 137 with PCOS and 75 without PCOS. Intervention(s): BMI, gonadotropins, insulin, androgens (T, androstenedione, DHEAS), 17 -hydroxyprogesterone, sex hormone-binding globulin, and triglycerides were studied. Glycemia and insulin response to the tolerance test (GTT) with a 100-g oral glucose load were also assessed in 103 women. Result(s): A good correlation between insulin and BMI was found in normal and obese women without hormonal dysfunction and in patients with or without PCOS. Good correlations, although lower, between insulin and T, and BMI, insulin, and T with triglycerides were also found in patients with PCOS. These patients fell into clearly distinct categories: with or without insulin resistance and with or without obesity, but slim women with PCOS had insulin and metabolic variables similar to those without PCOS, and most obese women with PCOS were insulin-resistant and more hyperandrogenic and hypertriglyceridemic. Conclusion(s): Insulin, androgens, and BMI are related in women both with PCOS and without PCOS, especially in obese ones. Insulin and metabolic indices are similar in lean women with PCOS and those without PCOS, but obese women with PCOS are more insulin-resistant, hyperandrogenic, and hypertriglyceridemic. Three types of disorders can be distinguished: simple nonhyperandrogenic obesity, typical nonhyperinsulinemic PCOS, and insulin-resistant PCOS. (Fertil Steril 1999;72: by American Society for Reproductive Medicine.) Key Words: Insulin, insulin resistance, hyperandrogenism, obesity, polycystic ovary syndrome Polycystic ovary syndrome (PCOS) is a complex clinical entity that probably includes several different pathologies. The condition affects a great number of women, especially infertile women. It is clinically indicated by menstrual disorders (oligomenorrhea or amenorrhea), hirsutism, and/or other signs of hyperandrogenism. Patients frequently are obese and, as mentioned, infertile. The ovaries appear thickened both ultrasonographically and laparoscopically. On histopathologic examination, sometimes the polycystic aspect predominates (multiple half-grown, 6 8-mm peripheral follicles), and in some other cases, hyperthecosis prevails (with fewer small follicles but with a large thecal hyperplasia), the latter being the real cause of hyperandrogenism. In terms of hormonal analysis, hyperandrogenism usually prevails in patients with PCOS ( 4-androstenedione [A] and/or T increased), but an alteration of the FSH/LH ratio (with predominance of the latter gonadotropin) can also be seen, together with a decrease in sex hormone-binding globulin (SHBG), an increase in 17 -hydroxy progesterone (17-OHP) and 32
2 DHEAS, an increase in insulin, and sometimes hyperinsulinemiaandinsulinresistance. Thesehyperinsulinemicinsulinresistant patients with PCOS are the most obese, hyperandrogenic, hypercholesterolemic, and hypertriglyceridemic. These women may develop hypertension, diabetes, or cardiovascular disease and suffer other severe vital and reproductive risks in the future. Therefore, insulin, androgens, and obesity are implicated in patients with PCOS, especially in the most severe cases. The definitions of these symptoms, the correlations between them, their mutual influences, their origins or causes, the characterization of the syndrome, and the consideration of PCOS as a heterogeneous group of disorders with different pathologies are controversial issues. In some studies it has been reported that hyperinsulinemia promotes hyperandrogenism in women with PCOS but not in normal ones and that hyperinsulinemia represents a universal feature of PCOS (1). Other reports show that obesity is related to hyperandrogenism and hyperinsulinemia (2, 3). However, other studies (4, 5) have not reported any relation between hyperinsulinemia and hyperandrogenism, and it is evident that not all obese women are hyperandrogenic or hyperinsulinemic. Furthermore, it does not appear that hyperandrogenism causes hyperinsulinemia or obesity. After ovary castration or the administration of GnRH analogues (6), insulin resistance continues in those women who suffer from it, and men with clear hyperandrogenism do not show any insulin resistance (unless pathologically). To help clarify these pathogenic aspects of PCOS; to evaluate the mutual influences among insulin, hyperandrogenism, and obesity; and to classify the different disorders included in PCOS, we studied and sought correlations among the following: [1] basal levels of insulin and insulin resistance (hyperresponse to 75 or 100 g oral glucose load), [2] androgens ( A, T, 17-OHP, DHEAS) and levels of hyperandrogenism (of T), and [3] body mass index (BMI) and grades of obesity (based on BMI), as well as some related metabolic anomalies (triglycerides), in normal women, patients with PCOS, and those with other non- PCOS endocrinopathies. MATERIALS AND METHODS Subjects and Study Design A total of 212 women were studied. One hundred thirteen patients with PCOS (88 noninsulin-resistant and 25 insulinresistant) and 61 women without PCOS were studied at the University Hospitals of Elche and San Juan. Women without PCOS included 26 normal women, 18 with obesity (BMI 30 kg/m 2 ), 12 with hyperprolactinemia, 10 with hypothalamic dysfunction or amenorrhea, and 13 with slight ovarian dysfunction or essential hirsutism. All women were examined clinically (e.g., general and gynecologic examinations, weight, height, blood pressure, Ferriman-Gallwey index). Hormonal and biochemical analyses, including gonadotropins, insulin, androgens ( A, T, DHEAS), 17-OHP, SHBG, triglycerides, and others, were performed during the first days of the cycle, or in any case, during the follicular phase. The women were analyzed retrospectively, although many had been studied previously in a prospective manner as part of other studies. SHBG had not been studied in all cases. Fifty-one patients in the PCOS group and 14 without PCOS had undergone a test of tolerance to a 100-g oral glucose load (or 75 g in 10 cases) to determine insulin and glycemia at baseline and at 30, 60, 120, and 180 minutes. Other determinations or studies (such as cortisol or ACTH test, or those performed in the luteal phase) were not considered here. To study the insulin response (or insulin resistance) to the glucose load in a wider number of patients, we included another 14 normal women and 24 women with PCOS who had been studied prospectively at the University Hospital of Alicante with a different analysis objective by two of the authors (P.M. and J.A.L.-F.). All of these additional subjects had also been studied at the beginning of the follicular phase, and apart from gonadotropin, insulin, androgen, 17-OHP, and SHBG levels, all of them had undergone an insulin and glycemia response test to a 100-g oral glucose load, and the blood samples were analyzed in the same Hormone Laboratory. Therefore, we analyzed 75 women without PCOS, 28 of them with a response test or curve of glycemia and insulin (with insulin resistance in 2), and 137 patients with PCOS, 75 of them with a curve of insulin and glycemia (with insulin resistance in 27). To catalogue and achieve a suitable distribution of the cases studied, we followed several criteria. [1] PCOS was diagnosed according to the characteristic clinical findings (various cycle alterations, obesity, hirsutism, and acne), endocrine data (high LH levels, LH/FSH ratio of 2, high androgen levels), and the appearance of polycystic ovaries on transvaginal ultrasonography according to the criteria of Adams et al. (1986) and Takahashi et al. (1994) (7 9). Specifically, PCOS was defined when the patient exhibited at least three of the following five signs or symptoms: LH/FSH ratio 2, A 4.5 ng/ml and/or T 0.8 ng/ml, ovaries with PCOS criteria in the transvaginal ultrasound examination (presence of 10 small [2 8 mm] peripheral follicles bilaterally, without dominance, around a dense core of stroma), amenorrhea or oligomenorrhea, and hirsutism or acne. [2] The diagnosis of PCOS was also based on the exclusion of other PCOS-like syndromes, including adrenal dysfunction, Cushing s syndrome, congenital adrenal hyperplasia, androgen-producing tumors, and thyroid dysfunction. However, within the PCOS group, we included patients with PCOS who had a slight partial deficiency of 21-OH (if the basal 17-OHP was 3 ng/ml and 6 ng/ml, or if at 1 hour FERTILITY & STERILITY 33
3 in the New s test [ACTH 250 U, IV] it was 6 ng/ml and 10 ng/ml) and patients with PCOS with an adrenal component if the DHEAS was 4 ng/ml and/or cortisol was 25 g/dl. In the group without PCOS, we included normal women and obese women with normal hormonal analysis (some of them were considered as a control group in other studies; others were obese women studied for this disorder). This group also included [1] women with hyperprolactinemia (if PRL was 25 ng/ml without other clinical or analytic data of PCOS); [2] those with hypothalamic dysfunction, including cases of delayed puberty, chronic psychic anovulation, and those with hypogonadism-hypogonadotropism; and [3] women with slight ovarian dysfunction and essential hirsutism, to refer to cases with menstrual delay, slight increase in androgens, ultrasonographic appearance of polycystic ovaries, or hirsutism, without the three criteria required to be included as PCOS. [3] Hyperinsulinemia was considered when basal insulin was 25 U/mL. Insulin resistance was recorded when the basal insulin was 30 U/mL and/or some point of the curve in the response test (at 1 hour) was 175 U/mL (10, 11). The 95th percentile and means 2 SDs of insulin levels in our studied normal women without hormonal dysfunction were 23 U/mL (baseline level), 157 U/mL (at 30 minutes), 175 U/mL (at 60 minutes), 93 U/mL (at 120 minutes), and 44 U/mL (at 180 minutes). [4] The BMI was calculated as weight in kg/m 2 and was considered normal at BMI 25 kg/m 2. Patients were considered clearly obese at BMI 30 kg/m 2. Setting and Assays Most of the patients were studied clinically and using transvaginal ultrasound by one of the authors (P.A.) at the University Hospital of Elche (until 1992) and San Juan (after 1992). Other patients were studied by other authors (P.M. and J.L.L.-F.) at the University Hospital of Alicante. However, all hormonal analyses were performed at the Hormone Laboratory of the General University Hospital of Alicante (M.M. and R.A.). FSH, LH, and PRL concentrations were measured by an immunoenzymatic assay (Abbott Laboratories, Madrid, Spain); E 2 and T were measured by a double-antibody RIA (ICN Biomedical Inc., Costa Mesa, CA). The intraassay and interassay coefficients of variation (CVs) were 10.6% and 11.9% for E 2 and 7.5% and 9% for T, respectively. Delta A was measured by a solid-phase RIA (Coat-a-Count; Diagnostic Products Corporation, Los Angeles, CA) with intraassay and interassay CVs of 9.4% and 11.6%, respectively. Insulin was determined by an immunoradiometric method with reagents provided by Medgenix Diagnostics (Biosource, Fleurus, Belgium). The intraassay and interassay CVs were 4.5% and 12.2%, respectively. DHEAS and 17- OHP were determined by a solid-phase RIA (Diagnostic Products Corporation). The intraassay and interassay CVs were 5% and 8% for 17-OHP and 6.5% and 8.2% for DHEAS. Finally, SHBG was measured by an immunoradiometric method (Spectria; Orion Diagnostica, Finland) with intraassay and interassay CVs of 4.9% and 5.5%, respectively. Statistical Analysis The data from the 212 subjects were introduced into a computer with the statistical package R-Sigma (Horus Hardware, 1990). First, a Kolmogorov-Smirnov test was applied to all groups and variables to evaluate the adjustment to a normal or symmetrical distribution. In cases of adjustment to a normal distribution, means and SDs were obtained, and then an unpaired t-test for independent variables was applied. If the Kolmogorov-Smirnov test was significant (P.05), showing an asymmetrical distribution, the median and 25th and 75th percentiles were obtained, and the Mann- Whitney U test was applied for the differences between groups. Correlation coefficients between different variables were obtained using Pearson s and Spearman s methods. Differences and correlations were considered statistically significant at P.05. RESULTS Table 1 shows the mean values of BMI and of serum concentrations in the follicular phase of gonadotropins, A, T, DHEAS, 17-OHP, insulin, SHBG, and triglycerides in normal and obese women and in PCOS and non-pcos endocrinopathies. Women without hormonal dysfunction were separated into nonobese (normal women) and obese women (BMI 30 kg/m 2 ), and the latter showed higher values of insulin and lower values of SHBG. There was also a statistically significant increase in T and a nonsignificant increase in triglycerides. There were no significant differences between normal or obese women and other non-pcos endocrinopathies, except for triglycerides (which were lower). In women without hormonal dysfunction (normal and obese women), correlations among BMI, insulin, T, SHBG, and triglycerides were highly significant between BMI and insulin, and BMI and T. Correlations were also statistically significant, but negative, between BMI and SHBG, and T and SHBG. In women with non-pcos endocrinopathies, the correlation between BMI and insulin was also statistically significant, but not the other correlations. Table 1 also shows the values of the same variables and analysis of correlations for patients with PCOS, with or without insulin resistance. These patients were compared with normal and obese women without hormonal dysfunction and between the groups. We found the following results. [1] Women with PCOS without insulin resistance had significantly higher LH, A, T, 17-OHP, and DHEAS, and decreased SHBG, in comparison with normal and obese women. [2] Women with PCOS and insulin resistance had normal LH but significantly higher T (even higher than 34 Acién et al. Insulin, androgens, and obesity Vol. 72, No. 1, July 1999
4 TABLE 1 Body mass index and serum levels in the follicular phase of gonadotropins, androgens, insulin, SHBG, and triglycerides, as well as correlations among them, in normal and obese women and in PCOS and non-pcos endocrinopathies. Studied variables (normal values) Normal women (n 22) Obese women without hormonal dysfunction (n 18) Women with non-pcos endocrinopathies (n 35) Women with PCOS without insulin resistance (n 110) Women with PCOS with insulin resistance (n 27) All women with PCOS (n 137) BMI ( 25 kg/m 2 ) * FSH level (3 14 miu/ml) LH level (3 20 miu/ml) ( ) (6.2 14) A level ( ng/ml) T level ( ng/ml) # Insulin level (8 25 U/mL) * SHBG level ( nmol/l) OHP level (0.3 3 ng/ml) (1 1.8) (1 1.8) DHEAS level ( ng/ml) Triglycerides ( mg/dl) Obese women (BMI 30 kg/m 2 ) (%) Insulin resistance (%) Significant correlations (r): Normal obese women BMI/insulin BMI/T Insulin/T BMI/SHBG T/SHBG BMI/triglycerides Insulin/triglycerides T/triglycerides Insulin/SHBG Note: Values are expressed as means SD or median (25th and 75th percentiles). SHBG was studied in 19, 7, 10, 36, 8, and 44 patients of each group. r correlation coefficient. * P.001 versus normal women. P.01 versus normal obese women. P.05 versus normal obese women. P.001 versus patients with PCOS without insulin resistance. P.001 versus normal obese women. P.01 versus normal women. # P.01 versus patients with PCOS without insulin resistance. PCOS without insulin resistance) and of course BMI, insulin, and triglycerides, whereas SHBG was decreased. [3] In the total group of PCOS versus normal and obese women, we observed that A, T, and DHEAS, and insulin, were significantly higher, and that SHBG was lower. Twenty percent of these women had insulin resistance versus 2.7% in non-pcos (only in obese women). Correlations were again positive and statistically significant between BMI and insulin in all women with PCOS, between insulin and T in those patients without insulin resistance, and between BMI, T, and triglycerides in the total group of patients with PCOS. The correlation between insulin and SHBG was still negative and statistically significant in women with PCOS without insulin resistance and in the total group of patients with PCOS. Table 2 shows the mean values and SDs (or the median and 25th and 75th percentiles) of the same indices as in Table 1 and correlations among them, comparing obese versus nonobese women in all patients with and without PCOS. Compared with nonobese women, obese women without PCOS had significantly higher insulin and triglycerides and lower SHBG. Among patients with PCOS, the obese ones had higher T, insulin, and triglycerides compared with the nonobese ones, and lower LH and SHBG. Both groups of PCOS, compared with the corresponding non- PCOS group (obese and nonobese), had higher A, T, and insulin; and in nonobese women with PCOS (vs. non- PCOS), besides, higher LH, 17-OHP, DHEAS, triglycerides, and BMI, and less SHBG. The percentage of insulin resistance in nonobese patients with PCOS was 6%, versus 0% in those without PCOS, and it was 57% in obese women with PCOS versus 8.7% in obese women without PCOS. Again, the correlation between BMI and insulin was significantly high in both women with FERTILITY & STERILITY 35
5 TABLE 2 Body mass index and serum levels in the follicular phase of gonadotropins, androgens, insulin, SHBG, and triglycerides, as well as correlations among them, in the total cases studied with or without PCOS, and in obese and nonobese women. Women without PCOS (n 75) Women with PCOS (n 137) Studied variables (normal values) Not obese (BMI 30 kg/m 2 ) (n 52) Obese (BMI 30 kg/m 2 )(n 23) Not obese (BMI 30 kg/m 2 ) (n 100) Obese (BMI 30 kg/m 2 ) (n 37) BMI ( 25 kg/m 2 ) * FSH level (3 14 miu/ml) LH level (3 20 miu/ml) 6.5 ( ) A level ( ng/ml) T level ( ng/ml) ( ) Insulin level (8 25 U/mL) * 9.4 ( ) SHBG level ( nmol/l) * # 17-OHP level (0.3 3 ng/ml) 1 ( ) (1 1.8) DHEAS level ( ng/ml) Triglycerides ( mg/dl) ** Obese women (BMI 30 kg/m 2 ) (%) Insulin resistance (%) (0) 2.7 (2/23) (6/100) 20 (21/37) Significant correlations (r) BMI/insulin BMI/T Insulin/T BMI/SHBG 0.40 T/SHBG 0.34 BMI/triglycerides Insulin/triglycerides T/triglycerides Insulin/SHBG Note: Values are expressed as means SD or median (25th and 75th percentiles). SHBG was studied in only 27, 9, 36, and 8 patients of each group. r 0.40 correlation coefficient. * P.001 versus nonobese women. P.01 versus the corresponding group, obese and nonobese women who do not have PCOS. P.001 versus nonobese women with PCOS. P.001 versus the corresponding group, obese and nonobese women who do not have PCOS. P.05 versus nonobese women with PCOS. P.05 versus the corresponding group, obese and nonobese women who do not have PCOS. # P.01 versus nonobese women with PCOS. ** P.01 versus nonobese women. PCOS and without PCOS, but less between BMI and T; and only significant between insulin and T in patients with PCOS. SHGB showed a negative correlation with BMI in non-pcos, and with insulin in patients with PCOS. Triglycerides also showed a statistically significant positive correlation with BMI and insulin in women with PCOS and without PCOS, and with T only in patients with PCOS. Although nonobese patients with PCOS had slightly more insulin and insulin resistance than the corresponding group without PCOS, this was probably due to the higher BMI in the former group. If only women with BMI 23 kg/m 2 were compared, there were no significant differences in BMI, insulin, and triglycerides, but there were differences in androgens and SHBG (not shown in any Table). On the other hand, a good correlation between T and insulin was found in those patients with PCOS who had a slight partial deficiency of 21-OH (n 15) or adrenal involvement (n 26) (r 0.71 and r 0.46, respectively), and also with the insulin response in those insulin-resistant patients (not shown in any Table). Figures 1 and 2 analyze the values of insulin, T, SHBG, and triglycerides, and the insulin response to the overload of glucose, as a function of the different values of BMI. In women without PCOS, obesity (higher BMI, especially 30 kg/m 2 ) was moderately related to higher insulin and T, lower SHBG, and higher triglycerides. With or without the inclusion of the two cases of insulin resistance, obesity in these women without PCOS also increased the insulin response to the glucose overload (Fig. 2A). In patients with PCOS, when cases of insulin resistance were excluded, obesity had less effect than in women without PCOS. Insulin scarcely increased; T showed no change, although there was an increase in triglycerides; and the 36 Acién et al. Insulin, androgens, and obesity Vol. 72, No. 1, July 1999
6 FIGURE 1 Variations in mean values of insulin (A), T(B), SHBG (C), and triglycerides (D) as a function of different values of BMI in women without PCOS (o), patients with PCOS without insulin resistance (Œ), and all women with PCOS ( ). FIGURE 2 (A), Insulin response to 100 g of glucose load in women without PCOS considering BMI 25 kg/m 2 ( ) versus BMI 35 kg/m 2 (}). (B), Insulin response to 100 g of glucose load in patients with PCOS according to the four groups of BMI: 25 kg/m 2 ( ), kg/m 2 (Œ ), kg/m 2 (FE), and 35 kg/m 2 (}{). Dotted lines PCOS without insulin resistance; solid lines all patients with PCOS. insulin response was hardly influenced. Nevertheless, if all patients with PCOS were considered (because of the insulinresistant patients), obesity or increased BMI clearly led to higher insulin and T, lower SHBG, and higher triglycerides (Fig. 1). The insulin response increased in a correlated and proportional way with the increase in BMI, making clear the mutual influence between obesity and insulin resistance in patients with PCOS (Fig. 2B). If the analysis was performed as a function of the different values of basal insulin, we observed that in women without PCOS, an increase in insulin (even within the normal limits in all cases) increased BMI and triglycerides, had little effect on T, and lowered SHBG. Perhaps this occurred because there were many obese women in the non-pcos group, and perhaps it could also be the other way around: Obese women had higher insulin and triglycerides and lower SHBG. FERTILITY & STERILITY 37
7 FIGURE 3 (A), Variations in insulin response to 100 g of glucose load in patients with PCOS according to four groups of basal insulin: 15 U/mL ( ), U/mL (Œ ), U/mL (E), and 35 U/mL ({). Dotted lines PCOS without insulin resistance; solid lines all patients with PCOS. (B), Variations in insulin response to 100 g of glucose load in patients with PCOS according to four groups of T levels: 0.5 ng/ml ( ), ng/ml (Œ ), ng/ml (FE), and 1.5 ng/ml (}{). Dotted lines PCOS without insulin resistance; solid lines all patients with PCOS. increase in T. The insulin response also increased slightly with T, but this could be because there were more obese women included. In fact, women with PCOS without insulin resistance showed exactly the same insulin response to the overload of glucose independent of the T values (Fig. 3B), thus showing that T had no influence on the insulin values or on the response to the overload of glucose in patients with PCOS. Nor did BMI, insulin, or SHBG change in relation to T in noninsulin-resistant patients with PCOS. However, in the total group of patients with PCOS (including the cases with insulin resistance) and with hyperandrogenism (T 1 ng/ml), there was a slight but statistically significant increase in BMI, insulin, and triglycerides, as well as in the insulin response (Fig. 3B). This could be due, however, to the hyperinsulinemia, the increased BMI, and the associated hyperandrogenism. DISCUSSION Thus, in women without PCOS (noninsulin resistant), when insulin increased (from a BMI increase), the insulin response to an overload of glucose increased as well. This did not occur in patients with PCOS without insulin resistance. However, in the total group of patients with PCOS (insulin-resistant included), when insulin increased, we observed a very strong hyperresponse of this (corresponding to insulin-resistant patients) (Fig. 3A). BMI, T, and triglycerides also increased when basal insulin did. Finally, if the analysis was performed as a function of the different values of T, then when there was a slight increase in T, in women without PCOS, there was a slight increase in BMI and a decrease in SHBG, without any modification of insulin and triglycerides. These findings again suggest that few changes were a consequence of obesity and not of an Prelevic (12) has recently pointed out that hyperinsulinemia was observed in 30% of slim women and in 75% of obese women with PCOS. Despite certain conceptual problems about PCOS, hyperinsulinemia, and insulin resistance, it seems evident that insulin and obesity are strongly correlated and that both influence each other regardless of whether women are normal or have PCOS, are normoandrogenic or hyperandrogenic. In some studies (4, 6, 13), it has been reported that both obese and nonobese women with PCOS were more insulin-resistant and hyperinsulinemic than age- and weight-matched normal women. However, other studies have failed to find hyperinsulinemia in slim women with PCOS, and with a thorough methodologic approach, insulin sensitivity was found to be normal in muscle, liver, and adipose tissue in slim women with PCOS (14). In our study, all hyperinsulinemic and insulin-resistant patients had BMI 25 kg/m 2 (and in 76% of cases, it was 30 kg/m 2 ), and although most of them had PCOS, a positive and significant correlation between BMI and insulin was present in all cases with or without PCOS. Slim patients with PCOS had insulin values similar to normal women of the same weight, even though the former were hyperandrogenic and had low SHBG. However, it is also true that insulin and insulin resistance are higher with a higher BMI, and the other way around, especially in women with PCOS (Figs. 1 and 2). Among normal women, and women without PCOS in general, there was a high correlation between BMI and insulin (r 0.75), so that obese women without PCOS had significantly higher insulin, and, in some cases, insulin resistance (with BMI of 38 kg/m 2 ). These normal obese women also had slightly higher T, lower SHBG, and higher triglycerides, suggesting that all this was due to obesity, with 38 Acién et al. Insulin, androgens, and obesity Vol. 72, No. 1, July 1999
8 a consequent decrease in sensitivity to insulin (increase in resistance). Among women with PCOS, there are both obese and slim women, and there was a correlation between BMI and insulin (and SHBG) that was lower than that in women without PCOS (r 0.58). In these women, there was also a smaller correlation between insulin and T, and BMI, insulin, and T with triglycerides. However, among these women with PCOS, two clearly differentiated groups can be distinguished according to the presence or absence of insulin resistance. [1] Women with PCOS without insulin resistance are simply more hyperandrogenic than normal women or those without PCOS: LH, A, T, 17-OHP, and DHEAS were higher and SHBG was lower; but there were no clear differences in BMI, insulin, insulin response, or even in triglycerides. [2] Women with PCOS with insulin resistance had normal values of LH but were more hyperandrogenic, with high BMI, hyperinsulinemia, and higher triglycerides. All of them were obese, and they naturally showed insulin hyperresponse, which increased with higher BMI, basal insulin, and (to a lesser extent) T. As mentioned earlier, slim women with PCOS showed insulin and metabolic indices similar to those of women without PCOS, although they had significantly higher LH and androgens and lower SHBG. Insulin seemed to have no influence. However, the obesity in most obese women with PCOS seemed to be due to or related to insulin resistance, and although some patients are simply obese (as among normal ones), the obese insulin-resistant women with PCOS are more hyperandrogenic with higher metabolic risks. Therefore, two different types of obesity seem to exist. Primary obesity is due perhaps to psychological and nutritional factors, to an alteration of leptin, or to an alteration in -endorphins of the endogenous opioid system. This type is probably a global obesity (type 1) or a gynecoid one (type 4) of Lefebvre et al. (3). Secondary obesity may be due to insulin resistance and related hormonal (androgens) and metabolic alterations (lipid metabolism); this would more likely be an android obesity (types 2 and 3 of Lefebvre et al.) (3). Primary obesity in severe cases also leads to insulin resistance, alterations of lipid metabolism, hyperleptinemia (increase in triglycerides, decrease in insulin receptors, and hyperinsulinemia), higher -endorphin levels, and lower SHBG (2, 15 17). Therefore, it also seems likely that two kinds of insulin resistance exist. The primary type is probably due to a genetic anomaly (genes involved in the secretion and action of insulin) and is related to hyperandrogenism. The secondary type may be a consequence of a pronounced global or gynecoid obesity. Based on our results, at least three entities or clearly defined disorders must be differentiated in patients with obesity and/or hyperandrogenism and/or hyperinsulinemia and insulin resistance. [1] Simple obesity is not hyperandrogenic but involves increased levels of insulin (sometimes with insulin resistance) and triglycerides, and decreased SHBG levels. [2] Typical PCOS is not hyperinsulinemic and is probably due to anomalies in the genetic coding of steroidogenic enzymes, therefore affecting the regulation of the secretion and action of androgens (18, 19). The increase in androgens will lead to various events, such as a decrease in SHBG, an increase in estrogens, an alteration in the pulsatile release of LH, an increase in serum LH, arrest of follicular development, and hyperthecosis. These events contribute to the vicious cycle that causes polycystic ovaries, apart from the possible intervention of genes regulating folliculogenesis, leading to higher hyperandrogenism (more follicles, more inhibin, more estrogens, less FSH, and more LH) and anovulation. Hyperinsulinemia is not evident in these patients, although it increases with BMI, but clinical signs are evident, including hyperandrogenism (acne, hirsutism), anovulation-amenorrhea, and the usual ultrasound appearance of the polycystic ovaries. Perhaps the most suitable treatment is antiandrogens (e.g., cyproterone acetate, flutamide, finasteride), the combination of ethinyl estradiol and cyproterone acetate as a contraceptive pill (7), or ovulation inducers. [3] As mentioned, insulin-resistant PCOS could be due to anomalies in the genes involved in the secretion and action of insulin. Franks et al. (18) concluded that the VNTR (variable number tandem repeats) of the insulin gene is a major susceptibility locus for certain patients with PCOS and may contribute to the mechanism of hyperinsulinemia and to the high risk of diabetes type 2 in women with PCOS. These patients may have hyperinsulinemia and insulin resistance, and therefore secondary android obesity, hyperleptinemia, alterations of lipid metabolism, anovulation, hyperthecosis, and secondary hyperandrogenism because of the decrease in SHBG and insulin-like growth factor binding protein-1 and the increase in -endorphins (1, 2, 18). Naturally, these women have high metabolic, atherogenic, hypertensive, renal, and cardiovascular risks. The most appropriate treatment is probably the combination of diet and oral antidiabetic drugs (metformin; or with less indication, troglitazone or diazoxide) (20, 21). Antagonist opioids (naloxone and naltrexone) also could be useful in these cases; the combination of GnRH analogues and a contraceptive pill containing ethinyl estradiol and cyproterone acetate has also been useful (7). Barbieri (22), Dale et al. (23), and other investigators have also described two groups of patients with PCOS, similarly differentiated. However, there can also be some mixed cases, and in PCOS groups with or without insulin resistance, some kind of adrenal involvement may occur. Moghetti et al. (24) reported that hyperinsulinemia may stimulate cytochrome P450c 17 activity in the adrenal glands of women with PCOS. We have observed the best correlation between insulin and T in women with PCOS who FERTILITY & STERILITY 39
9 had a slight partial deficit of 21-OH or adrenal involvement. But the three entities mentioned could have a defined genetic origin, show clinical differences, and have different consequences. Likewise, the therapeutic possibilities will be different. In short, insulin, androgens, and BMI are related in women with PCOS and without PCOS, especially in obese ones; and three types of disorders can be differentiated: simple nonhyperandrogenic obesity, typical nonhyperinsulinemic PCOS, and insulin-resistant PCOS. The latter occurs in the most hyperandrogenic obese women and causes the highest metabolic, renal, and cardiovascular risks. References 1. Nestler JE. Insulin regulation of human ovarian androgens. Hum Reprod 1997;12(Suppl 1): Pasquali R, Casimirri F, Vicennati V. Weight control and its beneficial effect on fertility in women with obesity and polycystic ovary syndrome. Hum Reprod 1997;12(Suppl 1): Lefebvre P, Bringer J, Renard E, Bonlet F, Clonet S, Jaffiol C. Influences of weight, body fat patterning and nutrition on the management of PCOS. Hum Reprod 1997;12(Suppl 1): Dunaif A, Graf M. Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulinresistant women with the polycystic ovary syndrome. J Clin Invest 1989;83: Rajkhowa M, Bicknell J, Jones M, Clayton R. Insulin sensitivity in women with polycystic ovary syndrome: relationship to hyperandrogenemia. Fertil Steril 1994;61: Dunaif A, Green G, Futterweit W, Dobrjansky A. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1990;70: Acién P, Mauri M, Gutierrez M. Clinical and hormonal effects of the combination gonadotropin-releasing hormone agonist plus oral contraceptive pills containing ethinyl-oestradiol (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian diseaserelated hyperandrogenism. Hum Reprod 1997;12: Falsetti L, Eleftherion G. Hyperinsulinemia in the polycystic ovary syndrome: a clinical, endocrine and echographic study in 240 patients. Gynecol Endocrinol 1996;10: Ciampelli M, Fulghesu AM, Murgia F, Guido M, Cucinelli F, Apa R, et al. Acute insulin response to intravenous glucagon in polycystic ovary syndrome. Hum Reprod 1998;13: Barbieri R, Ryan K. Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. Am J Obstet Gynecol 1983;147: Millet-Serrano A, Hernández A, Millet A, Dolz M, Rodríguez M. Ovario poliquístico: resistencia a la insulina. Obstet Ginecol Esp 1998; 7: Prelevic G. Insulin resistance in polycystic ovary syndrome. Curr Opin Obstet Gynecol 1997;9: Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 1995;96: Ovensen P, Moller J, Ingerslev HJ, Jorgensen JO, Mengel A, Schmitz O, et al. Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1993;77: Gennarelly G, Holte J, Wide L, Berne C, Lithell H. Is there a role for leptin in the endocrine and metabolic aberrations of polycystic ovary syndrome? Hum Reprod 1998;13: Geisthövel F, Meysing A, Brabant G. C-peptide and insulin, but not C19-steroids, support the predictive value of body mass index on leptin in serum of premenopausal women. Hum Reprod 1998;13: Segal K, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996;45: Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R, et al. The genetic bases of polycystic ovary syndrome. Hum Reprod 1997;12: Gharani N, Waterworth DM, Batty S, White D, Gilling-Smith C, Conway GS, et al. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 1997;6: Van Montfrans JM, van Hoof MHA, Hompes PGA, Lambalk CB. Treatment of hyperinsulinaemia in polycystic ovary syndrome? Hum Reprod 1998;13: Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998;69: Barbieri RL. Hyperandrogenic disorders. Clin Obstet Gynecol 1990; 33: Dale PO, Tanbo T, Vaaler S, Abyholm T. Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations. Fertil Steril 1992;58: Moghetti P, Castello R, Negri C, Tosi F, Spiazzi G, Brun E, et al. Insulin infusion amplifies 17-alpha-hydroxy-corticosteroid intermediate response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metab 1996;81: Acién et al. Insulin, androgens, and obesity Vol. 72, No. 1, July 1999
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic
More informationWEIGHT CHANGE AND ANDROGEN LEVELS DURING CONTRACEPTIVE TREATMENT OF WOMEN AFFECTED BY POLYCYSTIC OVARY
ENDOCRINE REGULATIONS, VOL. 40, 119-123, 2006 119 WEIGHT CHANGE AND ANDROGEN LEVELS DURING CONTRACEPTIVE TREATMENT OF WOMEN AFFECTED BY POLYCYSTIC OVARY J. VRBIKOVA, K. DVORAKOVA, M. HILL, L. STARKA Institute
More informationROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)
ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Definition: the diagnostic criteria Evidence of hyperandrogenism, biochemical &/or clinical (hirsutism, acne & male pattern baldness). Ovulatory dysfunction; amenorrhoea; oligomenorrhoea
More informationMetformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome
FERTILITY AND STERILITY VOL. 69, NO. 4, APRIL 1998 Copyright 1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Metformin therapy improves
More informationPolycystic Ovarian Syndrome (PCOS) LOGO
Polycystic Ovarian Syndrome (PCOS) Ma qianhong Ob/Gyn Department LOGO Contents Epidemiology and Definition Pathophysiology, Endocrinological Features Diagnostic Criteria Treatment Prognosis Introduction
More informationThe contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome
Human Reproduction vol.14 no.2 pp.307 311, 1999 The contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome E.Carmina 1, F.Gonzalez 2, A.Vidali
More informationInvestigation of adrenal functions in patients with idiopathic hyperandrogenemia
European Journal of Endocrinology (26) 155 37 311 ISSN 84-4643 CLINICAL STUDY Investigation of adrenal functions in patients with idiopathic hyperandrogenemia Hulusi Atmaca, Fatih Tanriverdi 1, Kursad
More informationAcute insulin response to intravenous glucagon in polycystic ovary syndrome
Human Reproduction vol.13 no.4 pp.847 851, 1998 Acute insulin response to intravenous glucagon in polycystic ovary syndrome Mario Ciampelli 1, Anna M.Fulghesu 1, Francesca Murgia 1, Maurizio Guido 1, Francesco
More informationEffect of troglitazone on endocrine and ovulatory performance in women with insulin resistance related polycystic ovary syndrome
FERTILITY AND STERILITY VOL. 71, NO. 2, FEBRUARY 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effect of troglitazone
More informationCase Questions. Polycystic Ovarian Syndrome: Treatment Goals and Options. Differential Diagnosis of Hyperandrogenic Anovulation
Polycystic Ovarian Syndrome: Treatment Goals and Options Marc Cornier, MD Division of Endocrinology, Metabolism and Diabetes Colorado Center for Health and Wellness University of Colorado School of Medicine
More informationSemih Tugrul, M.D., Tayfun Kutlu, M.D., Oya Pekin, M.D., Elif Baglam, M.D., H useyin Kıyak, M.D., and Ozay Oral, M.D.
Clinical, endocrine, and metabolic effects of acarbose, a a-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome Semih Tugrul, M.D., Tayfun Kutlu, M.D., Oya
More informationPolycystic Ovary Syndrome (PCOS):
Polycystic Ovary Syndrome (PCOS): Current diagnosis and treatment Anatte E. Karmon, MD Disclosures- Anatte Karmon, MD No financial relationships to disclose 2 Objectives At the end of this presentation,
More informationOverview of Reproductive Endocrinology
Overview of Reproductive Endocrinology I have no conflicts of interest to report. Maria Yialamas, MD Female Hypothalamic--Gonadal Axis 15 4 Hormone Secretion in the Normal Menstrual Cycle LH FSH E2, Progesterone,
More informationClinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes
POLYCYSTIC OVARY SYNDROME Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes Ettore Guastella, M.D., a Rosa Alba Longo, M.D., b and Enrico Carmina, M.D. b a Department
More informationPCOS and Obesity DUB is better treated by OCPs
PCOS and Obesity DUB is better treated by OCPs Dr. Ritu Joshi Senior consultant Fortis escorts Hospital, Jaipur Chairperson Family welfare com. FOGSI (20092012) Vice President FOGSI 2014 Introduction One
More informationCREATING A PCOS TREATMENT PLAN. Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University
CREATING A PCOS TREATMENT PLAN Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University PCOS: CREATING A TREATMENT PLAN Good treatment plans are based on sound and complete evaluations History of
More informationThe prevalence of polycystic ovaries in healthy women
Acta Obstet Gynecol Scand 1999; 78: 137 141 Copyright C Acta Obstet Gynecol Scand 1999 Printed in Denmark all rights reserved Acta Obstetricia et Gynecologica Scandinavica ISSN 0001-6349 ORIGINAL ARTICLE
More information12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman
Polycystic Ovarian Syndrome (PCOS) for the Family Physician Barbara S. Apgar MD, MS Professor or Family Medicine University of Michigan Ann Arbor, Michigan Important references for PCOS Endocrine Society
More informationObesity differentially affects serum levels of androstenedione and testosterone in polycystic ovary syndrome
Obesity differentially affects serum levels of androstenedione and testosterone in polycystic ovary syndrome Carlos Moran, M.D., M.Sc., a,b Jose L. Renteria, M.D., M.Sc., a Segundo Moran, M.D., M.Sc.,
More informationNitasha Garg 1 Harkiran Kaur Khaira. About the Author
https://doi.org/10.1007/s13224-017-1082-4 ORIGINAL ARTICLE A Comparative Study on Quantitative Assessment of Blood Flow and Vascularization in Polycystic Ovary Syndrome Patients and Normal Women Using
More informationSyndrome in Clinical Practice
Focus on CME at the University of British Columbia Polycystic Ovarian Syndrome in Clinical Practice Although polycystic ovarian syndrome was first recognized and described more than 60 years ago, the primary
More informationINSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME An Overview
INSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME An Overview University of PNG School of Medicine & Health Sciences Division of Basic Medical Sciences PBL MBBS III VJ Temple 1 Insulin Resistance: What is
More informationCan Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?
www.ijpm.in www.ijpm.ir Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome? Ferdous Mehrabian, Maryam Afghahi Department
More informationDetermining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs)
Abstract: Determining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs) Ashraf Olabi, Ghena Alqotini College of medicine, Aleppo University Hospital Obstetrics and Gynacology, Syria.
More informationReproductive FSH. Analyte Information
Reproductive FSH Analyte Information 1 Follicle-stimulating hormone Introduction Follicle-stimulating hormone (FSH, also known as follitropin) is a glycoprotein hormone secreted by the anterior pituitary
More informationMetformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative Study
The Journal of Obstetrics and Gynecology of India (September-October 2012) 62(5):551 556 DOI 10.1007/s13224-012-0183-3 ORIGINAL ARTICLE Metformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative
More informationMetformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome
IJMS Vol 36, No 2, June 2011 Original Article Metformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome Marzieh Farimani Sanoee 1, Nosrat Neghab 1, Soghra
More informationPOLYCYSTIC OVARIAN SYNDROME Laura Tatpati, MD Reproductive Endocrinology and Infertility. Based on: ACOG No. 108 Oct 2009; reaffirmed 2015
POLYCYSTIC OVARIAN SYNDROME Laura Tatpati, MD Reproductive Endocrinology and Infertility Based on: ACOG No. 108 Oct 2009; reaffirmed 2015 NO DISCLOSURES PATIENT 26 years old presents with complaint of
More informationFeedback inhibition of insulin secretion and insulin resistance in polycystic ovarian syndrome with and without obesity
European Review for Medical and Pharmacological Sciences 1997; 1: 17-171 Feedback inhibition of insulin secretion and insulin resistance in polycystic ovarian syndrome with and without obesity d. sinagra,
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Kathleen Colleran, MD Professor of Medicine University of New Mexico HSC Presented for COMM-TC May 4, 2012 Objectives Understand the pathophysiology of PCOS Understand how to
More informationX/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Copyright 2006 by The Endocrine Society doi: /jc.
0021-972X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Printed in U.S.A. Copyright 2006 by The Endocrine Society doi: 10.1210/jc.2005-1457 EXTENSIVE CLINICAL EXPERIENCE Relative
More informationDiabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome
Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome John E. Nestler, M.D. William Branch Porter Professor of Medicine Chair, Department of Internal Medicine Virginia Commonwealth University
More information2-Hypertrichosis:- Hypertrichosis is the
Hirsutism And Virilization Hirsutism:- Is the development of androgen-dependent dependent terminal body hair in a woman in places in which terminal hair is normally not found, terminal body hairs are the
More informationProf.Dr. Nabil Lymon Head of Internal Medicine Department
By Prof.Dr. Nabil Lymon Head of Internal Medicine Department Definitions: Hirsutism: Is the presence of terminal hair in androgendependent sites where hair does not normally grow in women. This hair growth
More informationInsulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome
European Journal of Endocrinology (2001) 144 509±515 ISSN 0804-4643 CLINICAL STUDY Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with
More informationReproductive outcome in women with body weight disturbances
Reproductive outcome in women with body weight disturbances Zeev Shoham M.D. Dep. Of OB/GYN Kaplan Hospital, Rehovot, Israel Weight Status BMI (kg/m 2 ) Underweight
More informationS. AMH in PCOS Research Insights beyond a Diagnostic Marker
S. AMH in PCOS Research Insights beyond a Diagnostic Marker Dr. Anushree D. Patil, MD. DGO Scientist - D National Institute for Research in Reproductive Health (Indian Council of Medical Research) (Dr.
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationclinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome
& clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome Zulfo Godinjak¹*, Ranka Javorić² 1 Gynecology and Obstetrics
More informationDepartment of Obstetrics and Gynecology, University of Modena, Modena, Italy
FERTILITY AND STERILITY VOL. 81, NO. 1, JANUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Metformin administration modulates
More informationPolycystic Ovary Syndrome Therapy Dr. Pilar Vigil MD, PhD, FACOG
Polycystic Ovary Syndrome Therapy Dr. Pilar Vigil MD, PhD, FACOG What is an ovulatory dysfunction? Mrs. Susana Godoy, Nurse-Midwife San José, Costa Rica Abril 2018 PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE
More informationHyperandrogenism. Dr Jack Biko. MB. BCh (Wits), MMED O & G (Pret), FCOG (SA), Dip Advanced Endoscopic Surgery(Kiel, Germany)
Hyperandrogenism Dr Jack Biko MB. BCh (Wits), MMED O & G (Pret), FCOG (SA), Dip Advanced Endoscopic Surgery(Kiel, Germany) 2012 Hyperandrogenism Excessive production of androgens Adrenal glands main source
More information12/27/2013. Kristen Cain, MD FACOG Reproductive Medicine Institute Sanford Health, Fargo ND
Kristen Cain, MD FACOG Reproductive Medicine Institute Sanford Health, Fargo ND 7% of all women 18-45 Obesity 1/3 of all US women Incidence of PCOS is increasing with increase obesity Obesity Irregular
More informationRelation of luteinizing hormone levels to body mass index in premenopausal women
FERTILITY AND STERILITY VOL. 69, NO. 3, MARCH 1998 Copyright 1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Relation of luteinizing
More informationMetfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study
Original Research Article Metfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study Allanki Suneetha Devi 1, Jalem Anuradha 2* 1 Associate Professor, Department of Obstetrics and Gynecology,
More informationWhat every dermatologist should know about Polycystic Ovary Syndrome (PCOS)
What every dermatologist should know about Polycystic Ovary Syndrome (PCOS) Kanade Shinkai, MD PhD University of California, San Francisco Associate Professor of Dermatology I have no conflicts of interest
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationAmenorrhoea: polycystic ovary syndrome
There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've
More informationJMSCR Vol 05 Issue 05 Page May 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i5.14 Hyperinsulinemia in Polycystic Ovary Syndrome
More informationPolycystic Ovary Syndrome
What is the polycystic ovary syndrome? Polycystic Ovary Syndrome The polycystic ovary syndrome (PCOS) is a clinical diagnosis characterized by the presence of two or more of the following features: irregular
More informationAbstract. Introduction. RBMOnline - Vol 10. No Reproductive BioMedicine Online; on web 15 November 2004
RBMOnline - Vol 10. No 1. 2005 100-104 Reproductive BioMedicine Online; www.rbmonline.com/article/1484 on web 15 November 2004 Article Metformin monotherapy in lean women with polycystic ovary syndrome
More informationDOES INSULIN RESISTANCE CAUSE HYPERANDROGENEMIA OR HYPERANDROGENEMIA CAUSES INSULIN RESISTANCE IN PCOS
DOES INSULIN RESISTANCE CAUSE HYPERANDROGENEMIA OR HYPERANDROGENEMIA CAUSES INSULIN RESISTANCE IN PCOS D R. G A N A P A T H I. B D E P T. O F E N D O C R I N O L O G Y S T. J O H N S M E D I C A L C O
More informationInternational Journal of Advanced Research in Biological Sciences ISSN : Research Article
International Journal of Advanced Research in Biological Sciences ISSN : 2348-8069 www.ijarbs.com Research Article Tamoxifen or Drospirenone and Ethinyl Estradiol: which is the first choice for infertile
More informationPrevalence of polycystic ovarian changes and polycystic ovary syndrome in premenopausal women with treated type 2 diabetes mellitus
Prevalence of polycystic ovarian changes and polycystic ovary syndrome in premenopausal women with treated type 2 diabetes mellitus Fahrettin Kelestimur, M.D., a Kürşad Unluhizarci, M.D., a Hür Baybuga,
More informationCase. 24 year old female presented to your office complaining of excess hair growth on her face and abdomen. Questions?
Hirsutism Case 24 year old female presented to your office complaining of excess hair growth on her face and abdomen Questions? Started around puberty with gradual progression Irregular menstrual cycle
More informationPrevalence of polycystic ovarian syndrome in the Buraimi region of Oman
Original Article Brunei Int Med J. 2012; 8 (5): 248-252 Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman Usha VARGHESE 1 and Shaji VARUGHESE 2, 1 Department of Internal Medicine
More informationEFFECT OF WEIGHT LOSS ON OVARIAN AND ADRENAL ANDROGEN SENSITIVITY. Department OB/GYN. EVMA Norfolk, Va Telephone: (804)
This study predates but predicts the use of glucophage, exercise and diet for the treatment of PCO. EFFECT OF WEIGHT LOSS ON OVARIAN AND ADRENAL ANDROGEN SENSITIVITY Principal Investigator: Hofheimer Hall
More informationHirsutism: Diagnosis and Treatment. Roger A. Lobo M.D. Columbia University
Hirsutism: Diagnosis and Treatment Roger A. Lobo M.D. Columbia University Signs of hyperandrogenism Acne, Hirsutism, Alopecia All explained by increased androgen production and/or increased sensitivity
More informationPREVALENCE OF METABOLIC SYNDROME IN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME A CROSS SECTIONAL STUDY THE TAMILNADU. Dr.M.G.R.
PREVALENCE OF METABOLIC SYNDROME IN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME A CROSS SECTIONAL STUDY Dissertation submitted to THE TAMILNADU Dr.M.G.R.MEDICAL UNIVERSITY In partial fulfillment of the requirement
More informationClinical study of polycystic ovarian syndrome (PCOS) in tertiary care centre
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Sowmya D et al. Int J Reprod Contracept Obstet Gynecol. 2017 Aug;6(8):3247-3251 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20173144
More informationNew PCOS guidelines: What s relevant to general practice
New PCOS guidelines: What s relevant to general practice Dr Michael Costello Fertility Specialist IVF Australia UNSW Royal Hospital for Women Sydney How do we know if something is new? Louvre Museum, Paris
More informationObjectives 1. Be able to describe the classic presentation and diagnostic criteria 2. Be able to explain long-term health concerns associated with the diagnosis 3. Understand what basic treatment options
More informationIMPACT OF NUTRITION ON GYNECOLOGICAL HEALTH OF FEMALE ADOLESCENTS
IMPACT OF NUTRITION ON GYNECOLOGICAL HEALTH OF FEMALE ADOLESCENTS Kedikova S. MD, PhD Medical University Sofia, Bulgaria University Hospital Maichin dom Sofia NUTRITION WHO - Nutrition is the intake of
More informationASSOCIATION OF INSULIN RESISTANCE AND SERUM 25 OH VITAMIN-D IN INDIAN WOMEN WITH POLYCYSTIC OVARY SYNDROME
RESEARCH ARTICLE ASSOCIATION OF INSULIN RESISTANCE AND SERUM 25 OH VITAMIN-D IN INDIAN WOMEN WITH POLYCYSTIC OVARY SYNDROME Amar Nagesh Kumar 1, Jupalle Nagaiah Naidu 2, Uppala Satyanarayana 3, Medabalmi
More informationPolycystic Ovary Disease: A Common Endocrine Disorder in Women
Polycystic Ovary Disease: A Common Endocrine Disorder in Women Paul Kaplan, M.D. Clinical Professor of Reproductive Endocrinology - OHSU Courtesy Senior Research Associate, Human Physiology University
More informationFrank Gonzalez, M.D.,* Lillie Chang, M.D., Theresa Horab, R.N.,* Frank Z. Stanczyk, Ph.D., Kent Crickard, M.D.,* and Rogerio A. Lobo, M.D.
FERTILITY AND STERILITY VOL. 71, NO. 3, MARCH 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Adrenal dynamic responses
More informationAchieving Pregnancy: Obesity and Infertility. Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center
Achieving Pregnancy: Obesity and Infertility Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center Disclosures Speakers Bureau EMD Serono Board of Directors Nurse
More informationTreatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy*
Gynecology-endocrinology FERTILITY AND STERILITY Copyright 1994 The American Fertility Society Printed on acid-free paper in U S. A. Treatment of hirsutism with a gonadotropin-releasing hormone agonist
More informationCorrelation Between Insulin, Leptin and Polycystic Ovary Syndrome
Original Article Correlation Between Insulin, Leptin and Polycystic Ovary Syndrome Mohamed Nabih El Gharib, Thoraya Elsayed Badawy 1 Departments of Obstetrics and Gynecology, 1 Clinical Pathology, Faculty
More informationPrevalence of Polycystic Ovarian Syndrome among urban adolescent girls and young women in Mumbai
Prevalence of Polycystic Ovarian Syndrome among urban adolescent girls and young women in Mumbai Principal Investigator Co- Investigators Consultant Collaborating Hospital Dr. Beena Joshi Dr. Srabani Mukherji
More informationSelection criteria of normal controls to predict reliable cut-off values of various endocrine parameters in infertility
J Obstet Gynecol India Vol. 55, No. 1 : January/February 2005 Pg 72-76 ORIGINAL ARTICLE The Journal of Obstetrics and Gynecology of India Selection criteria of normal controls to predict reliable cut-off
More informationThe Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (1), Page 63-69
The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (1), Page 63-69 Effect of Metformin Only versus Effect of Metformin and Corticosteroids after Laparoscopic Ovarian Drilling on Ovulation
More informationTitle of Guideline (must include the word Guideline (not protocol, policy, procedure etc)
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Guideline for the Investigation and Management of Polycystic Ovary Syndrome Author: Contact Name and Job Title
More informationJMSCR Vol 04 Issue 12 Page December 2016
www.jmscr.igmpublication.org Impact Factor 5.244 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v4i12.103 Study of Effect of Metformin in PCOS
More informationInfertility for the Primary Care Provider
Infertility for the Primary Care Provider David A. Forstein, DO FACOOG Clinical Associate Professor Obstetrics and Gynecology University of South Carolina School of Medicine Greenville Disclosure I have
More information16 YEAR-OLD OBESE FEMALE WITH OLIGOMENORRHEA
16 YEAR-OLD OBESE FEMALE WITH OLIGOMENORRHEA Katie O Sullivan, MD Adult/Pediatric Endocrinology Fellow University of Chicago ENDORAMA Thursday, September 4th, 2014 Disclosures No financial interests. Will
More informationSCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY
1 SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL SEMINAR: SEX HORMONES PART 1 An Overview What are steroid hormones? Steroid
More informationSAMPLE REPORT. Order Number: PATIENT. Age: 40 Sex: F MRN:
Patient: Age: 40 Sex: F MRN: SAMPLE PATIENT Order Number: Completed: Received: Collected: SAMPLE REPORT Progesterone ng/ml 0.34 0.95 21.00 DHEA-S mcg/dl Testosterone ng/ml 48 35 0.10 0.54 0.80 430 Sex
More informationClinical correlation with biochemical status in polycystic ovarian syndrome
J Obstet Gynecol India Vol. 55, No. 1 : January/February 2005 Pg 67-71 ORIGINAL ARTICLE The Journal of Obstetrics and Gynecology of India Clinical correlation with biochemical status in polycystic ovarian
More informationEfficacy of metformin supplementation during ovarian stimulation of lean PCOS patients undergoing in vitro fertilization
Acta Obstetricia et Gynecologica. 2009; 88: 563568 ORIGINAL ARTICLE Efficacy of metformin supplementation during ovarian stimulation of lean PCOS patients undergoing in vitro fertilization BANU KUMBAK
More informationAFTER THE FIRST publications reporting the treatment
0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(8):4593 4598 Printed in U.S.A. Copyright 2005 by The Endocrine Society doi: 10.1210/jc.2004-2283 Metformin and Weight Loss in
More informationIntroduction. Original Article
Iran J Reprod Med Vol. 10. No. 4. pp: 307-314, July 2012 Original Article Correlation of biochemical markers and clinical signs of hyperandrogenism in women with polycystic ovary syndrome (PCOS) and women
More informationPolycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology
Polycystic Ovarian Syndrome Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology Outline Definition Symptoms Causal factors Diagnosis Complications Treatment Why are we talking about
More informationGynecology-endocrinology
Gynecology-endocrinology FERTILITY AND STERILITY Copyright c 1994 The American Fertility Society Vol. 61, No.5, May 1994 Printed on acid-free paper in U. S. A. Treatment of moderate and severe hirsutism
More informationComparative study of metabolic profile of women presenting with polycystic ovary syndrome in relation to body mass index
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Akshaya S et al. Int J Reprod Contracept Obstet Gynecol. 2016 Aug;5(8):2561-2565 www.ijrcog.org pissn 2320-1770 eissn 2320-1789
More informationDr Stella Milsom. Endocrinologist Fertility Associates Auckland. 12:30-12:40 When Puberty is PCO
Dr Stella Milsom Endocrinologist Fertility Associates Auckland 12:30-12:40 When Puberty is PCO Puberty or Polycystic Ovary Syndrome? Stella Milsom Endocrinologist Auckland DHB, University of Auckland,
More informationEstimation of serum 25 hydroxy vitamin D level and its correlation with metabolic and endocrine dysregulation in women with PCOS
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Solanki V et al. Int J Reprod Contracept Obstet Gynecol. 2017 Jul;6(7):3085-3090 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20172939
More informationNormalization of hyperinsulinemia by chronic opioid receptor blockade in hyperandrogenemic women
POLYCYSTIC OVARY SYNDROME Normalization of hyperinsulinemia by chronic opioid receptor blockade in hyperandrogenemic women Dijana Hadžiomerović, M.D., Bernhard Rabenbauer, M.D., and Ludwig Wildt, M.D.
More informationThe effect of metformin on hirsutism in polycystic ovary syndrome
European Journal of Endocrinology (2002) 147 217 221 ISSN 0804-4643 CLINICAL STUDY The effect of metformin on hirsutism in polycystic ovary syndrome Christopher J G Kelly and Derek Gordon Stobhill Hospital,
More informationTHE PREVALENCE AND ETIOLOGY OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AS A CAUSE OF FEMALE INFERTILITY IN CENTRAL TRAVANCORE
NSave Nature to Survive 9(1): 01-06, 2014 www.thebioscan.in THE PREVALENCE AND ETIOLOGY OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AS A CAUSE OF FEMALE INFERTILITY IN CENTRAL TRAVANCORE K. ROY GEORGE AND N.
More informationClinical Profile Polycystic Ovarian Syndrome Cases
ORIGINAL RESEARCH www.ijcmr.com - 100 Cases Himabindu Sangabathula 1, Neelima Varaganti 1 ABSTRACT Introduction: Polycystic ovary syndrome (PCOS) is most common endocrine disorders of reproductive age
More informationResearch. Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome
Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome Claudia Gagnon, Jean-Patrice Baillargeon @ See related article page 951 DOI:10.1503/cmaj.060607 Abstract
More informationlactotrophs 120 min- FSH 60 min- LH Hypothalamus GnRH pituitary Estradiol +/- Progesterone _ FSH L H Ovary Uterus Ovulation Antral follicle >2mm
lactotrophs Hypothalamus GnRH 120 min- 60 min- LH Progesterone _ pituitary L H + Ovary + Estradiol +/- Uterus Antral follicle >2mm Ovulation Preovulatory follicles atresia Follicular phase Luteal phase
More informationChapter 2 Clinical Evaluation of PCOS
Chapter 2 Clinical Evaluation of PCOS Richard S. Legro, M.D. Professor, Department of Obstetrics and Gynecology, Penn State College of Medicine, Milton S. Hershey Medical Center, Hershey PA Correspondence
More informationPolycystic ovary syndrome
Jon Havelock, MD, FRCSC Polycystic ovary syndrome Therapy for this reproductive and metabolic disorder remains focused on managing symptoms, including infertility caused by anovulation, and reducing long-term
More informationEndocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound
Human Reproduction vol.12 no.5 pp. 905 909, 1997 Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound E.Carmina 1, L.Wong 2, L.Chang 2, R.J.Paulson 2, disturbance of the IGF/IGFBP-l
More informationMetformin in early pregnancy and abortions. Laure Morin-Papunen, MD, PhD Dept. of Obstetrics and Gynecology University Hospital of Oulu, Finland
Metformin in early pregnancy and abortions Laure Morin-Papunen, MD, PhD Dept. of Obstetrics and Gynecology University Hospital of Oulu, Finland PCOS and miscarriage risk Metformin and miscarriage risk
More informationOutlook PCOS: a diagnostic challenge
RBMOnline - Vol 8. No 6. 2004 644-648 Reproductive BioMedicine Online; www.rbmonline.com/article/1274 on web 5 April 2004 Outlook PCOS: a diagnostic challenge Dr Ricardo Azziz Dr Azziz is currently Chairman
More informationPOLYCYSTIC OVARY SYNDROME INA S. IRABON,MD, FPOGS,FPSRM,FPSGE OBSTETRICS AND GYNECOLOGY REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY
POLYCYSTIC OVARY SYNDROME INA S. IRABON,MD, FPOGS,FPSRM,FPSGE OBSTETRICS AND GYNECOLOGY REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY TO DOWNLOAD LECTURE DECK MAIN REFERENCE Comprehensive Gynecology 7 th
More information